Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim

Feb 17 2014

• By Sarah Karlin-Smith

Related Content

Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods

Oct 04 2004

Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says

Jun 20 2005

NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer

Feb 12 2014

NSAID Panel Could Give Naproxen Labeling Edge

Feb 05 2014

FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training

Nov 26 2013

Related Companies

Pfizer Inc.

Additional Topics

United States Regulation Post Market Regulation & Studies Safety Risk Management Advisory Committees OTC Drugs BioPharmaceutical Consumer

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window